UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2026
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes ☐ No
☒
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published
two announcements (the “Public Notices”) to the Australian Securities Exchange on November 18, 2026, titled:
| |
- |
CEO Address |
| |
|
|
| |
- |
Results of Annual General Meeting |
A copy of the Public Notices is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
EXHIBITS
Exhibit
Number |
|
Description |
| 99.1 |
|
CEO Address |
| 99.2 |
|
Results of Annual General Meeting |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
IMMURON LIMITED |
| |
|
|
| Date: November 18, 2026 |
By: |
/s/ Olga Smejkalova |
| |
|
Olga Smejkalova |
| |
|
Company Secretary |
Exhibit 99.1
ASX/NASDAQ Announcement
18 November 2026
2026
Annual General Meeting - CEO Address
Immuron Limited (ASX: IMC; NASDAQ: IMRN) attaches the CEO
Address to be delivered by Chief Executive Officer, Steve Lydeamore, at today’s Annual General Meeting.
- - - END - - -
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN),
is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for
the treatment of infectious diseases.
About Travelan®
Travelan® is an orally administered
passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder
that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized
preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent
colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine
on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce
the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health
product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold
as a dietary supplement for digestive tract protection.
Travelers’ diarrhea (TD)
TD is generally defined as the passage
of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus
in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung
et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income
regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly
affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the
leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter
spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).
Immuron Platform Technology
Immuron’s proprietary technology
is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing
highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment
of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses
this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying
nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform
can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
IMM-124E (Travelan®)
IMM-124E was developed using Immuron’s
platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine
containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels
of antibodies against selected surface antigens from the most common strains of ETEC. (Otto et al., 2011)
The resultant hyperimmune colostrum IMM-124E
from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin (Sears
et al., 2017).
The antibodies produced in IMM-124E have
been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range of LPS
antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core ‘R’ region of LPS from
the 13 serotypes used in the ETEC vaccine.
IMM-124E is manufactured into a tablet form referred
to as Travelan®.
IMM-529
Immuron is developing IMM-529 as an adjunctive therapy in combination
with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies
targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment of normal gut flora,
providing an attractive oral preventative for recurrent CDI.
Immuron is collaborating with Dr. Dena Lyras and her team at
Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate
hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin
B (TcB), the spores and the surface layer proteins of the vegetative cells.
This unique 3-target approach has yielded promising results
in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence
(67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies cross-react with
whole cell lysates of many different human strains of C. diff including hypervirulent strains.
To our knowledge, IMM-529 is, to date, the only
investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).
ProIBS®
Immuron has an exclusive distribution agreement
with Calmino goup AB for the territories of Australia and New Zealand for ProIBS®. ProIBS® - to help patients treat
IBS symptoms ProIBS® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating
and unsettled bowel movements (diarrhoea and/or constipation). ProIBS® contains AVH200®, derived from the
plant Aloe barbadensis. Mill. AVH200® has gel forming components which support the intestinal mucosal barrier. As IBS
is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use –as
ProIBS® is. The product is safe, and no interactions with other medications are known. Science-driven innovative Calmino
group AB, the developer of ProIBS®, conducted a usability study among 1,003 users. PROIBS® was helpful
for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone
else. To learn more please check: www.proibs.eu.
Irritable bowel syndrome (IBS) is a common condition where you
experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or
mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms of IBS include:
abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the two.(healthdirect.gov.au)
According to available data, the IBS treatment market in Australia is estimated to be a part of the broader "Digestives & Intestinal
Remedies" market, generating a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.(Statista)
References
Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea
during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.
Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies
targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5
Leung AK, Robson WL, Davies HD. Travelers’ diarrhea. Adv
Ther. Jul-Aug; 23(4): 519-27; 2006
Otto W, Najnigier B, Stelmasiak T and Robins-Browne RM. Randomized
control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli
in volunteers Scandinavian Journal of Gastroenterology 46: 862– 868; 2011.
Riddle MS, Sanders JW, Putnam SD, and Tribble DR. Incidence,
etiology, and impact of diarrhea among long-term travelers’ (US military and similar populations): A systematic review. American
Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.
Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N,
Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune
Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.
Steffen R. Epidemiology of travelers' diarrhea. J Travel Med.
24(suppl_1): S2-S5; 2017.
For more information visit: https://www.immuron.com.au/ and
https://www.travelan.com
Subscribe
to Immuron’s InvestorHub: Here
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

11 AGM PRESENTATION 18 NOVEMBER, 2026 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO

22 2 Certain statements made in this presentation are forward -looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward -looking statements. Although Immuron believes the forward -looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward -looking statements. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority. SAFE HARBOR STATEMENT FY2027 results in this presentation are subject to audit review.

Immuron is a company transitioning from development-led to commercially focused growth. Revenue trends remain positive, cash is sufficient to support operations, and management is seeking external partners for IMM-529 and Travelan® to unlock value while limiting funding risk. The principal valuation catalyst is a successful transaction for IMM-529, which management highlights as a potentially large market opportunity (Clostridioides difficile infection; Lumanity peak sales estimate in the U.S. US$400 million). Research & Development 2 pipeline assets to be partnered for development and commercialization Global footprint Australia, US, Canada and expanding Technology Platform Safe and potentially transformational approach to gut infections Our Products • Reduce the risk of Traveller's Diarrhoea • Sold in pharmacies Australia-wide • Available in Australia, USA and Canada • Treatment of symptoms associated with Irritable Bowel Syndrome (IBS) • Sold in pharmacies Australia-wide • Exclusive distribution agreement executed for the United States in September 2026 • Immuron's core strength lies in its ability to program cows to produce high levels of specific polyclonal antibodies (immunoglobulins) through vaccination. • Orally Active: Unlike many biologics that require injection, Immuron's bovine antibodies are naturally hardy. They survive the harsh acidic environment of the human stomach to work directly in the Gastrointestinal (GI) tract. • Precision Targeting: The platform can be "tuned" to target specific bacteria, viruses, or toxins by changing the vaccine. • Dual-Action Mechanism: The products don't just target the pathogens; they prevent them from sticking to the gut wall and neutralize the inflammatory toxins they release. • No reported serious adverse events or safety signals. Safety demonstrated in repeat-dose animal toxicity studies, immunohistochemical assessments showing no off-target cross-reactivity and bacterial reverse-mutation testing confirming it is non-mutagenic. Technology Platform Corporate Research Independent Buy recommendation NEW

4 FY26 Financial Achievements Global Sales Revenue $7.7m Up 6% Australian Sales Revenue $5.8m Up 10% United States Sales Revenue $1.8m Up 7% Up 13% in $USD Gross Profit Margin 64.5% 0.9% decline1 Net Profit $(3.8)m $1.4m improvement Cash $9.0m $6.2m2 improvement 1. Gross Profit Margin was slightly lower due to sales mx with a higher percentage of sales coming from Australia which has a lower margin than the United States 2. $3.0 million was held in Term Deposits on 30 June 2025 (30 June 2026: Nil)

5 FY26 Clinical Achievements and Operational Highlights FDA approval IMM-529 IND Travelan® n=851 trial completed New U.S. Department of Defense subaward New product launch in Australia A yellow circle with white letters AI t d t t Engaged Pullan Consulting to support partnering IMM-529 Strategic reset aimed at profitability and reduced cash burn

6 Continued strong sales growth Global + FY27 YTD October AUD$3.0 million up 10% on prior year Australia + FY27 YTD October AUD$2.5 million up 16% on prior year North America + FY27 YTD Oct AUD$0.5 million down 11% on prior year + USA FY27 YTD Oct AUD$0.5 million down 19% on prior year + Canada FY27 YTD Oct AUD$0.1 million up 150% on prior year Global Year to Date Jul - Sep Oct - Dec Jan - Mar Apr - Jun FY25 1.5 $ 2.5 $ 1.3 $ 2.0 $ FY26 2.0 $ 2.2 $ 1.5 $ 2.0 $ FY27 2.2 $

7 FY27 Outlook Continued Travelan® sales growth Portfolio expansion • Evaluating additional in- licensing opportunities • Developing new products Sales expansion • Planned UK launch • Exploring partnerships to expand sales channels in the United States Partnering update for IMM-529 Continued improvement in profitability and reduced cash burn Cash to fund operations through FY27 – FY28 Strategic initiatives update for Immuron Limited

EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: IMMURON INVESTOR HUB COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH
Exhibit 99.2

ASX/NASDAQ Announcement
18 November 2026
2026 Annual General Meeting Results
In accordance with ASX Listing Rule 3.13.2
and Section 251AA(2) of the Corporations Act 2001 Immuron Limited (ASX: IMC; NASDAQ: IMRN or the Company) advises that the shareholders
of the Company passed Resolutions 1 and 2 at today’s Annual General Meeting. Resolutions 3, 4, 5 were not carried.
In accordance with ASX Listing Rule
3.13.2(f), the Company advises that more than 25% of the votes cast on Resolution 1 were against the adoption of the 2026 Remuneration
Report and therefore constitutes a “first strike” under section 250U of the Act.
All resolutions put to the meeting were carried by way of
a poll. Details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.
This announcement was authorised for release by the Company
Secretary.
- - - END - - -
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian
biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment
of infectious diseases.
About
Travelan®
Travelan® is an orally administered
passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder
that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation
of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization
and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register
for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal
disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce
the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
Travelers’ diarrhea (TD)
TD is generally defined as the passage
of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus
in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung
et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income
regions (Steffen, 2017). Deployed US military personnel, essentially
representing a long-term traveller population, are particularly affected given their population dynamics and the context in which they
seek care and treatment (Connor
et al., 2012). Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces,
with diarrheagenic E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle
et al., 2006).
Immuron Platform Technology
Immuron’s proprietary technology
is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing
highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment
of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses
this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying
nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform
can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
IMM-124E (Travelan®)
IMM-124E was developed using Immuron’s
platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine
containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels
of antibodies against selected surface antigens from the most common strains of ETEC. (Otto
et al., 2011)
The resultant hyperimmune colostrum
IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin
(Sears et al., 2017).
The antibodies produced in IMM-124E
have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range
of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core ‘R’ region of LPS
from the 13 serotypes used in the ETEC vaccine.
IMM-124E
is manufactured into a tablet form referred to as Travelan®.
IMM-529
Immuron is developing IMM-529 as an adjunctive therapy in
combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI).
IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment
of normal gut flora, providing an attractive oral preventative for recurrent CDI.
Immuron is collaborating with Dr. Dena Lyras and her
team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised
to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components.
IMM-529 targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.
This unique 3-target approach has
yielded promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052);
(2) Protection of disease recurrence (67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC).
Importantly IMM-529 antibodies cross-react with whole cell lysates of many different human strains of C. diff including
hypervirulent strains.
To our knowledge, IMM-529 is, to date, the only investigational
drug that has shown therapeutic potential in all three phases of the disease (Hutton
et al., 2017).
ProIBS®
Immuron has an exclusive distribution agreement with Calmino
goup AB for the territories of Australia and New Zealand for ProIBS®. ProIBS® - to help patients treat IBS symptoms ProIBS®
is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea
and/or constipation). ProIBS® contains AVH200®, derived from the plant Aloe barbadensis. Mill. AVH200® has gel forming components
which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it is essential to have
a treatment appropriate for long-term use –as ProIBS® is. The product is safe, and no interactions with other medications are
known. Science-driven innovative Calmino group AB, the developer of ProIBS®, conducted a usability study among 1,003 users. PROIBS®
was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone
else. To learn more please check: www.proibs.eu.
Irritable bowel syndrome (IBS) is a common condition where
you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels
or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms of IBS include:
abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the two.(healthdirect.gov.au)
According to available data, the IBS treatment market in Australia is estimated to be a part of the broader “Digestives & Intestinal
Remedies” market, generating a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.(Statista)
References
Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea
during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.
Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine
antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017).
https://doi.org/10.1038/s41598-017-03982-5
Leung AK, Robson WL, Davies HD. Travelers’ diarrhea.
Adv Ther. Jul-Aug; 23(4): 519-27; 2006
Otto W, Najnigier B, Stelmasiak T and Robins-Browne RM.
Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia
coli in volunteers Scandinavian Journal of Gastroenterology 46: 862– 868; 2011.
Riddle MS, Sanders JW, Putnam SD, and Tribble DR. Incidence,
etiology, and impact of diarrhea among long-term travelers’ (US military and similar populations): A systematic review. American
Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.
Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos
N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune
Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.
Steffen R. Epidemiology of travelers’ diarrhea. J Travel
Med. 24(suppl_1): S2-S5; 2017.
For more information visit: https://www.immuron.com.au/
and https://www.travelan.com
Subscribe to Immuron’s InvestorHub: Here
FORWARD-LOOKING STATEMENTS:
This
press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs and any other statements that are not historical facts.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that
could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,
perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to
preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent
and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect
any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except
as required by law.
Immuron Limited
Annual General Meeting
Wednesday, 18 November 2026
Results
of Meeting
The following information is provided in accordance with
section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2
| Resolution
details | |
Instructions
given to validly appointed proxies
(as at proxy close) | | |
Number
of votes cast on the poll (where applicable) | | |
Resolution
Result | |
| |
| Resolution | |
Resolution
Type | |
For | | |
Against | | |
Proxy’s
Discretion | | |
Abstain | | |
For | | |
Against | | |
Abstain* | | |
Carried
/
Not Carried | |
If
s250U
applies | |
| 1.
Adoption of Remuneration Report | |
Ordinary | |
| 15,879,052 | | |
| 19,131,403 | | |
| 8,889,087 | | |
| 237,557 | | |
| 24,768,139 | | |
| 19,131,403 | | |
| 237,557 | | |
Carried | |
| Yes | |
| | |
| |
| 36.17 | % | |
| 43.58 | % | |
| 20.25 | % | |
| | | |
| 56.42 | % | |
| 43.58 | % | |
| | | |
| |
| | |
| 2.
Re-Election of Director – Dr Jeannette Anne Joughin | |
Ordinary | |
| 24,415,792 | | |
| 17,024,326 | | |
| 8,889,087 | | |
| 59,920 | | |
| 33,304,879 | | |
| 17,024,326 | | |
| 59,920 | | |
Carried | |
| n/a | |
| | |
| |
| 48.51 | % | |
| 33.83 | % | |
| 17.66 | % | |
| | | |
| 66.17 | % | |
| 33.83 | % | |
| | | |
| |
| | |
| 3.
Approval of increased placement capacity (Special Resolution) | |
Special | |
| 24,110,129 | | |
| 17,292,629 | | |
| 8,889,087 | | |
| 97,280 | | |
| 32,999,216 | | |
| 17,292,629 | | |
| 97,280 | | |
Not Carried | |
| n/a | |
| | |
| |
| 47.94 | % | |
| 34.38 | % | |
| 17.68 | % | |
| | | |
| 65.62 | % | |
| 34.38 | % | |
| | | |
| |
| | |
| 4.
Renewal of Omnibus Incentive Plan | |
Ordinary | |
| 12,712,219 | | |
| 22,474,513 | | |
| 8,889,087 | | |
| 61,280 | | |
| 21,601,306 | | |
| 22,474,513 | | |
| 61,280 | | |
Not Carried | |
| n/a | |
| | |
| |
| 28.84 | % | |
| 50.99 | % | |
| 20.17 | % | |
| | | |
| 49.01 | % | |
| 50.99 | % | |
| | | |
| |
| | |
| 5.
Election of Non-Board Endorsed Candidate – Mr Param Lally | |
Ordinary | |
| 14,261,898 | | |
| 24,917,754 | | |
| 8,892,888 | | |
| 2,316,585 | | |
| 14,261,898 | | |
| 33,810,642 | | |
| 2,316,585 | | |
Not Carried | |
| n/a | |
| | |
| |
| 29.67 | % | |
| 51.83 | % | |
| 18.50 | % | |
| | | |
| 29.67 | % | |
| 70.33 | % | |
| | | |
| |
| | |
| * | Votes cast by a person who abstains on an item are not counted
in calculating the required majority on a poll. |